Risk of Intracranial Hemorrhage With Protease-Activated Receptor-1 Antagonists | Zendy

Meng Lee | Zendy; Jeffrey L. Saver | Zendy; KeunSik Hong | Zendy; HsiuChuan Wu | Zendy; Bruce Ovbiagele | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Risk of Intracranial Hemorrhage With Protease-Activated Receptor-1 Antagonists

Author(s) -

Meng Lee,

Jeffrey L. Saver,

KeunSik Hong,

HsiuChuan Wu,

Bruce Ovbiagele

Publication year - 2012

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.112.670604

Subject(s) - medicine , relative risk , antagonist , placebo , randomized controlled trial , number needed to harm , intracerebral hemorrhage , clinical trial , number needed to treat , confidence interval , anesthesia , pathology , receptor , subarachnoid hemorrhage , alternative medicine

Recent clinical trial data suggest that protease-activated receptor-1 (PAR-1) antagonists may increase the risk of intracranial hemorrhage. Our objective was to investigate the qualitative and quantitative risks of intracranial hemorrhage in patients receiving PAR-1 antagonist therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research